282 related articles for article (PubMed ID: 35716323)
1. The immunosuppressive role of indoleamine 2, 3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies.
Hosseinalizadeh H; Mahmoodpour M; Samadani AA; Roudkenar MH
Med Oncol; 2022 Jun; 39(9):130. PubMed ID: 35716323
[TBL] [Abstract][Full Text] [Related]
2. The role of IDO in brain tumor immunotherapy.
Zhai L; Lauing KL; Chang AL; Dey M; Qian J; Cheng Y; Lesniak MS; Wainwright DA
J Neurooncol; 2015 Jul; 123(3):395-403. PubMed ID: 25519303
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies.
Zhai L; Bell A; Ladomersky E; Lauing KL; Bollu L; Sosman JA; Zhang B; Wu JD; Miller SD; Meeks JJ; Lukas RV; Wyatt E; Doglio L; Schiltz GE; McCusker RH; Wainwright DA
Front Immunol; 2020; 11():1185. PubMed ID: 32612606
[TBL] [Abstract][Full Text] [Related]
4. Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma.
Zhai L; Ladomersky E; Dostal CR; Lauing KL; Swoap K; Billingham LK; Gritsina G; Wu M; McCusker RH; Binder DC; Wainwright DA
Brain Behav Immun; 2017 May; 62():24-29. PubMed ID: 28179106
[TBL] [Abstract][Full Text] [Related]
5. Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod.
Lukas RV; Juhász C; Wainwright DA; James CD; Kennedy E; Stupp R; Lesniak MS
J Neurooncol; 2019 Jan; 141(1):111-120. PubMed ID: 30415456
[TBL] [Abstract][Full Text] [Related]
6. IDO1 in cancer: a Gemini of immune checkpoints.
Zhai L; Ladomersky E; Lenzen A; Nguyen B; Patel R; Lauing KL; Wu M; Wainwright DA
Cell Mol Immunol; 2018 May; 15(5):447-457. PubMed ID: 29375124
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
Song X; Si Q; Qi R; Liu W; Li M; Guo M; Wei L; Yao Z
Front Immunol; 2021; 12():800630. PubMed ID: 35003126
[TBL] [Abstract][Full Text] [Related]
8. Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma.
Zhai L; Bell A; Ladomersky E; Lauing KL; Bollu L; Nguyen B; Genet M; Kim M; Chen P; Mi X; Wu JD; Schipma MJ; Wray B; Griffiths J; Unwin RD; Clark SJ; Acharya R; Bao R; Horbinski C; Lukas RV; Schiltz GE; Wainwright DA
Clin Cancer Res; 2021 Dec; 27(23):6514-6528. PubMed ID: 34479957
[TBL] [Abstract][Full Text] [Related]
9. Indoleamine 2,3-dioxygenase 1 is highly expressed in glioma stem cells.
Ozawa Y; Yamamuro S; Sano E; Tatsuoka J; Hanashima Y; Yoshimura S; Sumi K; Hara H; Nakayama T; Suzuki Y; Yoshino A
Biochem Biophys Res Commun; 2020 Apr; 524(3):723-729. PubMed ID: 32035622
[TBL] [Abstract][Full Text] [Related]
10. The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy.
Zhai L; Dey M; Lauing KL; Gritsina G; Kaur R; Lukas RV; Nicholas MK; Rademaker AW; Dostal CR; McCusker RH; Raizer JJ; Parsa AT; Bloch O; Wainwright DA
J Clin Neurosci; 2015 Dec; 22(12):1964-8. PubMed ID: 26279502
[TBL] [Abstract][Full Text] [Related]
11. Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma.
Bollu LR; Bommi PV; Monsen PJ; Zhai L; Lauing KL; Bell A; Kim M; Ladomersky E; Yang X; Platanias LC; Matei DE; Bonini MG; Munshi HG; Hashizume R; Wu JD; Zhang B; James CD; Chen P; Kocherginsky M; Horbinski C; Cameron MD; Grigorescu AA; Yamini B; Lukas RV; Schiltz GE; Wainwright DA
J Med Chem; 2022 Dec; 65(23):15642-15662. PubMed ID: 36410047
[TBL] [Abstract][Full Text] [Related]
12. The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.
Gostner JM; Becker K; Überall F; Fuchs D
Expert Opin Ther Targets; 2015 May; 19(5):605-15. PubMed ID: 25684107
[TBL] [Abstract][Full Text] [Related]
13. Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib.
Riess C; Schneider B; Kehnscherper H; Gesche J; Irmscher N; Shokraie F; Classen CF; Wirthgen E; Domanska G; Zimpfer A; Strüder D; Junghanss C; Maletzki C
Front Immunol; 2020; 11():55. PubMed ID: 32117235
[TBL] [Abstract][Full Text] [Related]
14. Tryptophan metabolism in brain tumors - IDO and beyond.
Platten M; Friedrich M; Wainwright DA; Panitz V; Opitz CA
Curr Opin Immunol; 2021 Jun; 70():57-66. PubMed ID: 33813026
[TBL] [Abstract][Full Text] [Related]
15. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
Zhai L; Spranger S; Binder DC; Gritsina G; Lauing KL; Giles FJ; Wainwright DA
Clin Cancer Res; 2015 Dec; 21(24):5427-33. PubMed ID: 26519060
[TBL] [Abstract][Full Text] [Related]
16. Indoleamine 2, 3-Dioxygenase: A Professional Immunomodulator and Its Potential Functions in Immune Related Diseases.
Heidari F; Ramezani A; Erfani N; Razmkhah M
Int Rev Immunol; 2022; 41(3):346-363. PubMed ID: 33118843
[TBL] [Abstract][Full Text] [Related]
17. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
Koblish HK; Hansbury MJ; Bowman KJ; Yang G; Neilan CL; Haley PJ; Burn TC; Waeltz P; Sparks RB; Yue EW; Combs AP; Scherle PA; Vaddi K; Fridman JS
Mol Cancer Ther; 2010 Feb; 9(2):489-98. PubMed ID: 20124451
[TBL] [Abstract][Full Text] [Related]
20. Molecular docking and dynamic simulation studies evidenced plausible immunotherapeutic anticancer property by Withaferin A targeting indoleamine 2,3-dioxygenase.
Reddy SV; Reddy KT; Kumari VV; Basha SH
J Biomol Struct Dyn; 2015; 33(12):2695-709. PubMed ID: 25671592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
